Moderna and Merck Release Phase 3 Data for Cancer Vaccine Candidate Intismeran Autogene

Moderna and Merck announced topline results from the Phase 3 INTerpath-001 trial for their investigational mRNA cancer therapy, intismeran autogene, in combination with KEYTRUDA, showing a 42% reduction in cancer recurrence or death risk compared to KEYTRUDA alone after about two years. The data was released prematurely due to an embargo breach, resulting in significant volatility in Moderna's stock price (MRNA).